- Home
- BIVI vs NCNA Comparison
BIVI vs NCNA Comparison
Compare BIVI & NCNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BIVI | NCNA |
|---|---|---|
| Founded | 2013 | 1997 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5M | 8.8M |
| IPO Year | 2013 | 2017 |
Fundamental Metrics
Financial Performance| Metric | BIVI | NCNA |
|---|---|---|
| Price | $1.46 | $2.16 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 56.8K | 46.2K |
| Earning Date | 05-11-2026 | 06-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.75 | $0.03 |
| 52 Week High | $9.09 | $10.00 |
Technical Indicators
Market Signals| Indicator | BIVI | NCNA |
|---|---|---|
| Relative Strength Index (RSI) | 55.79 | 59.83 |
| Support Level | $1.42 | $2.07 |
| Resistance Level | $1.52 | $2.27 |
| Average True Range (ATR) | 0.08 | 0.19 |
| MACD | -0.00 | 0.09 |
| Stochastic Oscillator | 71.43 | 86.98 |
Price Performance
Historical ComparisonAbout BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.
About NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.